NASDAQ:LEGN 31 May 2026

Legence Shares Fall Despite S&P Ratings Bump

Legence Shares Fall Despite S&P Ratings Bump

Legence Corp. shares fell 5.9% to $83.69 Friday, closing near session lows as industrial stocks dropped after a strong U.S. jobs report. S&P Global Ratings upgraded Legence Holdings LLC to BB- from B+ and shifted its outlook to positive, citing lower private-equity ownership and strong first-quarter results. Legence’s amended $995 million term loan now carries a lower rate of SOFR plus 2.00%.
June 6, 2026
Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus

Legend Biotech Heads Into Monday After a Rough Week, ASCO in Focus

Legend Biotech shares fell 3.89% Friday to $27.16, down 7.5% for the week, ahead of a Sunday investor event at the ASCO cancer conference. The company plans to present early Phase 1 data for its experimental CAR-T therapy LB2102 and updates on CARVYKTI. Investors are watching for potential stock movement when markets reopen Monday. CARVYKTI sales rose 62% year-on-year to $597 million in Q1.
May 31, 2026